How does Tesamorelin preserve somatostatin feedback?

Tesamorelin has a short half-life of approximately 26 minutes, meaning it is rapidly cleared from the circulation. This allows the somatostatin-mediated negative feedback loop to remain active: as GH rises following Tesamorelin administration, somatostatin increases and acts to suppress further GH release, resulting in a natural GH pulse followed by return to baseline. Long-acting GHRH analogs like CJC-1295 with DAC provide continuous GHRH receptor stimulation that blunts this feedback, producing sustained elevated GH rather than pulsatile secretion.

Is Tesamorelin studied in non-HIV metabolic conditions?

Yes. Post-approval research has examined Tesamorelin in healthy aging adults, abdominal obesity without HIV, and for cognitive function effects. Investigator-sponsored trials and post-hoc analyses from the HIV lipodystrophy trials have examined secondary outcomes including lipid parameters, cardiovascular risk markers, IGF-1 levels, and cognitive performance, expanding the research context beyond the approved indication.

What distinguishes Tesamorelin from CJC-1295 in GH research?

Tesamorelin is a full-length GHRH(1-44) analog with a short half-life that preserves physiological GH pulsatility and somatostatin feedback. CJC-1295 with DAC is a modified shorter GHRH fragment that binds albumin to achieve a 6 to 8 day half-life, producing sustained GHRH receptor activation and blunted feedback. Tesamorelin is better suited to research requiring physiological GH patterns; CJC-1295 is better suited to research requiring sustained GH axis stimulation.

Compound Reference

Tesamorelin

Q: What is Egrifta and how does it relate to Tesamorelin?

Egrifta is the FDA-approved brand name pharmaceutical containing Tesamorelin as its active ingredient. It was approved by the FDA in November 2010 for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy, based on Phase 3 clinical trial data from the Falutz et al. NEJM study. Tesamorelin and Egrifta refer to the same compound; Egrifta is the commercial pharmaceutical form while Tesamorelin is the generic name of the GHRH analog.

An FDA-approved GHRH analog studied for physiological GH pulse stimulation and visceral adipose tissue reduction in metabolic research models.

GHRH analog (full-length)C₂₂₁H₃₆₆N₆₄O₆₇SApprox. 26 minutes (subcutaneous, clinical)

GH Axis StimulationVisceral Fat ResearchMetabolic Body CompositionFDA-Approved PharmacologyGHRH Receptor Activation

Overview

Tesamorelin is a synthetic analog of full-length GHRH(1-44), stabilized by the addition of a trans-3-hexenoic acid group to its N-terminus. It activates the GHRH receptor to stimulate pulsatile pituitary GH release while preserving somatostatin-mediated negative feedback, resulting in physiologically patterned GH secretion. Tesamorelin is FDA-approved under the trade name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, based on Phase 3 clinical trial data published by Falutz et al. in the New England Journal of Medicine (2010). This regulatory approval makes it one of the most clinically validated peptide compounds in metabolic research.

Quick Reference

Regulatory status: FDA-approved as Egrifta for HIV lipodystrophy
Structure: GHRH(1-44) with trans-3-hexenoic acid N-terminal modification
Half-life: Approx. 26 minutes (subcutaneous)
Landmark study: Falutz et al., NEJM, 2010
Purity standard: >=98% by HPLC

Mechanism

How It Works

Tesamorelin activates the GHRH receptor on pituitary somatotroph cells, stimulating GH synthesis and pulsatile release through the cAMP/PKA signaling pathway. Unlike CJC-1295 with DAC, its short half-life allows the somatostatin-mediated negative feedback loop to remain intact, producing more physiological GH pulsatility. The resulting GH elevation promotes lipolysis in visceral adipose tissue and increases IGF-1 production.

Research Highlights

Key findings from the published preclinical literature.

FDA Approval for HIV Lipodystrophy (Egrifta)

Falutz et al. (NEJM, 2010) documented significant visceral adipose tissue reduction in HIV-infected patients with lipodystrophy in Phase 3 randomized controlled trials, providing the evidence base for Tesamorelin FDA approval as Egrifta in 2010.

Visceral Adipose Tissue Reduction Mechanisms

Research has documented that Tesamorelin-stimulated GH elevation promotes lipolysis in visceral adipose depots through GH receptor activation in adipocytes, with documented reductions in trunk fat measured by DEXA and CT scan in clinical trials.

Cognitive and Metabolic Secondary Outcomes

Clinical trial secondary endpoints and post-hoc analyses have examined Tesamorelin effects on lipid profiles, insulin-like growth factor levels, cognitive function measures, and cardiovascular risk markers in HIV lipodystrophy and healthy aging populations.

Physiological GH Pulsatility Preservation

Pharmacokinetic studies have characterized Tesamorelin stimulation of GH as preserving the pulsatile pattern and somatostatin feedback regulation that characterize physiological GH secretion, distinguishing it from long-acting GHRH analogs that produce sustained elevated GH levels.

Research Connections

Related research areas, stacks, and comparisons involving this compound.

Frequently Asked Questions

Source This Compound

Tesamorelin is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply, same-day dispatch before 2 PM EST. For in-vitro research use only.

View Tesamorelin Product Sourcing Guide

All compounds are strictly for in-vitro research use only and not intended for human consumption.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research